Low-level viremia is associated with non-B subtypes in patients infected with HIV with virological success following HAART introduction

Journal of Medical Virology

Volumn 85, Issue 6, 2013, Pages 953-958

  Saison, Julien ^a,b,c,d   Tardy, Jean Claude ^a   Scholtes, Caroline ^a,c,d   Icard, Vinca ^a   Trabaud, Mary Anne ^a   Perpoint, Thomas ^b   Chidiac, Christian ^b,c,d   Ecochard, René ^b,c   André, Patrice ^a,c,d   Ferry, Tristan ^b,c,d  

^a CROIX ROUSSE HOSPITAL   (France)

^b HCL   (France)

^c UNIVERSITÉ LYON 1   (France)

^d CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

Author keywords

B subtype; HIV reservoir; Undetectability; Very low level viremia; Viral latency

Indexed keywords

PROTEINASE INHIBITOR;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT CODING; VIREMIA; VIRUS LATENCY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD; VIREMIA; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84876400601     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23553     Document Type: Article

References (38)

1. Abbas W, Herbein G. 2012. Molecular understanding of HIV-1 latency. Adv Virol 2012: 574967.
2. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, Schneider T. 2011. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 117: 2791-2799.
3. Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, Coffin JM, Eron J, Cohen M, Margolis DM. 2010. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS ONE 5: e9390.
4. Bonora S, Nicastri E, Calcagno A, Gonzalez de Requena D, D'Ettorre G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M. 2009. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: A cross-sectional evaluation. J Med Virol 81: 400-405.
5. Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, Arkin AP. 2010. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 84: 5958-5974.
6. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J. 2010. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16: 460-465.
7. Charpentier C, Landman R, Laouenan C, Joly V, Hamet G, Damond F, Brun-Vezinet F, Mentre F, Descamps D, Yeni P. 2012. Persistent low-level HIV-1 RNA between 20 and 50copies/mL in antiretroviral-treated patients: Associated factors and virological outcome. J Antimicrob Chemother 67: 2231-2235.
8. Chege D, Kovacs C, La Porte C, Ostrowski M, Raboud J, Su D, Kandel G, Brunetta J, Kim CJ, Sheth PM, Kaul R, Loutfy MR. 2012. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: A randomized controlled trial. AIDS 26: 167-174.
9. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15: 893-900.
10. Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS. 2011. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 204: 135-138.
11. Dahl V, Lee E, Peterson J, Spudich SS, Leppla I, Sinclair E, Fuchs D, Palmer S, Price RW. 2011. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis 204: 1936-1945.
12. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, O'Shea A, Callender M, Spivak A, Brennan T, Kearney MF, Proschan MA, Mican JM, Rehm CA, Coffin JM, Mellors JW, Siliciano RF, Maldarelli F. 2009. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 106: 9403-9408.
13. Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, Phillips AN, Geretti AM. 2012. Plasma HIV-1 RNA detection below 50copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 54: 724-732.
14. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 340: 1614-1622.
15. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM, Alatrakchi N, Jacobson JM, Wiegand A, Kearney M, Coffin JM, Mellors JW, Eron JJ. 2010. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: A randomized controlled trial. PLoS Med 7: e1000321.
16. Gianotti N, Galli L, Racca S, Salpietro S, Cossarini F, Spagnuolo V, Barda B, Canducci F, Clementi M, Lazzarin A, Castagna A. 2012. Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50copies/mL. J Antimicrob Chemother 67: 213-217.
17. Girard PM, Katlama C, Pialoux G. 2011. DOIN Editors, Wolters Kluwer France, Rueil-Malmaison, France, p 477.
18. Haim-Boukobza S, Morand-Joubert L, Flandre P, Valin N, Fourati S, Sayon S, Lavignon M, Simon A, Girard PM, Katlama C, Calvez V, Marcelin AG. 2011. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1copy/ml. AIDS 25: 341-344.
19. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG. 2011. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 203: 960-968.
20. Havlir DV, Koelsch KK, Strain MC, Margot N, Lu B, Ignacio CC, Miller MD, Wong JK. 2005. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis 191: 1164-1168.
21. Holguin A, Sune C, Hamy F, Soriano V, Klimkait T. 2006. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol 36: 264-271.
22. Katsoulidou A, Rokka C, Issaris C, Haida C, Tzannis K, Sypsa V, Detsika M, Paraskevis D, Hatzakis A. 2011. Comparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from Greece. Virol J 8: 10.
23. Lawrence P, Lutz MF, Saoudin H, Fresard A, Cazorla C, Fascia P, Pillet S, Pozzetto B, Lucht F, Bourlet T. 2006. Analysis of polymorphism in the protease and reverse transcriptase genes of HIV type 1 CRF02-AG subtypes from drug-naive patients from Saint-Etienne, France. J Acquir Immune Defic Syndr 42: 396-404.
24. Llibre JM, Buzon MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutierrez M, Palmer S, Stevenson M, Blanco J, Martinez-Picado J, Clotet B. 2012. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: A randomized 48-week study. Antivir Ther 17: 355-364.
25. Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G, Quinzan G, Soavi L, Iannotti N, Malfatto E, Leone S. 2012. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr 60: 473-482.
26. Martin-Blondel G, Saune K, Vu Hai V, Marchou B, Delobel P, Izopet J, Cuzin L, Massip P. 2012. Factors associated with a strictly undetectable viral load in HIV-1-infected patients. HIV Med 13: 568-573.
27. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F. 2010. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 50: 912-919.
28. Miri L, Ouladlahsen A, Kettani A, Bensghir R, Marhoum Elfilali K, Wakrim L. 2012. Characterization of protease resistance-associated mutations in HIV type 1 drug-naive patients following the increasing prevalence of the CRF02_AG strain in Morocco. AIDS Res Hum Retroviruses 28: 571-577.
29. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105: 3879-3884.
30. Palmer S, Josefsson L, Coffin JM. 2011. HIV reservoirs and the possibility of a cure for HIV infection. J Intern Med 270: 550-560.
31. Palmisano L, Giuliano M, Nicastri E, Pirillo MF, Andreotti M, Galluzzo CM, Bucciardini R, Fragola V, Andreoni M, Vella S. 2005. Residual viraemia in subjects with chronic HIV infection and viral load <50copies/ml: The impact of highly active antiretroviral therapy. AIDS 19: 1843-1847.
32. Peeters M, Aghokeng AF, Delaporte E. 2010. Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. Clin Microbiol Infect 16: 1525-1531.
33. Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N, Sekaly RP, Boulassel MR. 2012. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: Results from a multicentre randomized clinical study. HIV Med 13: 291-296.
34. Ruelle J, Debaisieux L, Vancutsem E, De Bel A, Delforge ML, Pierard D, Goubau P. 2012. HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability. BMC Infect Dis 12: 100.
35. Swanson P, de Mendoza C, Joshi Y, Golden A, Hodinka RL, Soriano V, Devare SG, Hackett J, Jr. 2005. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J Clin Microbiol 43: 3860-3868.
36. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Gunthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. 2012. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308: 387-402.
37. Widdrington J, Payne B, Medhi M, Valappil M, Schmid ML. 2011. The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART. J Infect 62: 87-92.
38. Yeni P. 2010. Prise en charge médicale des personnes infectées par le VIH. Médecine-Science Flammarion, Paris, France, p 152.